Chapter 7
Effects of TNF-α on Cardiac Function
Bo Yang, Douglas F. Larson,
Douglas F. Larson
Search for more papers by this authorBo Yang, Douglas F. Larson,
Douglas F. Larson
Search for more papers by this authorBook Editor(s):Ronald Ross Watson,
Douglas F. Larson,
Ronald Ross Watson
Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona
Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA
Search for more papers by this authorDouglas F. Larson
Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA
Search for more papers by this authorFirst published: 30 August 2007
Summary
This chapter contains section titled:
-
Introduction
-
TNF-á and TNF-á receptors
-
TNF-á and cardiac contractile function
-
Mechanisms of TNF-α induced contractile dysfunction
-
Sphingosine pathway (NO-independent pathway
-
Clinical trials of targeting TNF-á in heart failure patients
-
References
References
- Meldrum D.R. Tumor necrosis factor in the Heart. Am J Physiol 1998; 274 (3 Pt 2): R577–95.
- Bozkurt B Kribbs SB Clubb F. et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97 (14): 1382–91.
- Cain BS Meldrum DR Dinarello C. et al. Tumor necrosis factor-alpha and interleukin-1beta synergisti-cally depress human myocardial function. Crit Care Med 1999; 27 (7): 1309–18.
- Kumar A Thota V Dee L Olson J Uretz E Parrillo J.E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183 (3): 949–58.
- Kumar A Brar R Wang P et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999; 276 (1 Pt 2): R265–76.
- Francis G.S. TNF-alpha and Heart failure: the difference between proof of principle and hypothesis testing. Circulation 1999; 99 (25): 3213–14.
- Oral H Dorn GW Mann D.L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997; 272 (8): 4836–42.
- Panas D Khadour FH Szabo C Schulz R. Proinflam-matory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 1998; 275 (3 Pt 2): H1016–23.
- Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999; 40 (2): 97–105.
- Torre-Amione G MacLellan W Kapadia S et al. Tumor necrosis factor-alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transplant Proc 1998; 30 (3): 875–7.
- Neta R Sayers TJ Oppenheim J.J. Relationship of TNF to interleukins. Immunol Ser 1992; 56: 499–566.
- Tartaglia LA Ayres TM Wong GH Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74 (5): 845–53.
- Ashkenazi A Dixit V.M. Death receptors: signaling and modulation. Science 1998; 281 (5381): 1305–8.
- Aderka D Engelmann H Maor Y Brakebusch C Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175 (2): 323–9.
- Engelmann H Aderka D Rubinstein M Rotman D Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264 (20): 11974–80.
- Cain BS Meldrum DR Joo K. et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998; 32 (2): 458–67.
- Sasayama S Matsumori A Kihara Y. New insights into the pathophysiological role for cytokines in Heart failure. Cardiovasc Res 1999; 42 (3): 557–64.
- Bryant D Becker L Richardson J et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97 (14): 1375–81.
- Franco F Thomas GD Giroir B et al. Magnetic resonance imaging and invasive evaluation of development of Heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1999; 99 (3): 448–54.
- Eichenholz PW Eichacker PQ Hoffman W. et al. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 1992; 263 (3 Pt 2): H668–75.
- Murray DR Freeman G.L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996; 78 (1): 154–160.
- Edmunds NJ Lal H Woodward B. Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused Heart: possible mechanisms for a decline in cardiac function. Br J Pharmacol 1999; 126 (1): 189–96.
- Alloatti G Penna C De Martino A Montrucchio G Ca-mussi G. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Cardiovasc Res 1999; 41 (3): 611–9.
- Goldhaber JI Kim KH Natterson PD Lawrence T Yang P Weiss J.N. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996; 271 (4 Pt 2): H1449–55.
- Kumar A Kosuri R Kandula P Dimou C Allen J Parrillo J.E. Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med 1999; 27 (2): 286–92.
- Yokoyama T Vaca L Rossen RD Durante W Hazarika P Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian Heart. J Clin Invest 1993; 92 (5): 2303–12.
- Sugishita K Kinugawa K Shimizu T et al. Cellular basis for the acute inhibitory effects of IL-6 and TNF-alpha on excitation-contraction coupling. J Mol Cell Cardiol 1999; 31 (8): 1457–67.
- Kim MY Linardic C Obeid L Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 1991; 266 (1): 484–9.
- Wiegmann K Schutze S Kampen E Himmler A Machleidt T Kronke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J Biol Chem 1992; 267 (25): 17997–8001.
- Xie QW Whisnant R Nathan C. Promoter of the mouse gene encodingcalcium-independentnitricoxidesynthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993; 177 (6): 1779–84.
- Nunokawa Y Ishida N Tanaka S. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem Biophys Res Commun 1994; 200 (2): 802–7.
- Stoclet JC Muller B Gyorgy K Andriantsiothaina R Kleschyov A.L. The inducible nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol 1999; 375 (1–3): 139–55.
- Kolesnick R.N. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 1991; 30 (1): 1–38.
- Schutze S Machleidt T Kronke M. The role of dia-cylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 1994; 56 (5): 533–41.
- Jayadev S Linardic CM Hannun Y.A. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem 1994; 269 (8): 5757–63.
- Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274 (5294): 1855–9.
- Dettbarn CA Betto R Salviati G Palade P Jenkins GM Sabbadini R.A. Modulation of cardiac sarcoplasmic retic-ulum ryanodine receptor by sphingosine. J Mol Cell Car-diol 1994; 26 (2): 229–42.
- McDonough PM Yasui K Betto, R et al. Control of cardiac Ca2+ levels. Inhibitory actions of sphingosine on Ca2+ transients and L-type Ca2+ channel conductance. Circ Res 1994; 75 (6): 981–9.
- Sabbadini RA Betto R Teresi A Fachechi-Cassano G Salviati G. The effects of sphingosine on sarcoplas-mic reticulum membrane calcium release. J Biol Chem 1992; 267 (22): 15475–84.
- Webster RJ Sabbadini RA Dettbarn CA Paolini P.J. Sph-ingosine effects on the contractile behavior of skinned cardiac myocytes. J Mol Cell Cardiol 1994; 26 (10): 1273–90.
- Meldrum DR Cleveland JC Jr, Cain BS Meng X Harken A.H. Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 1998; 65 (2): 439–43.
- Krown KA Yasui K Brooker M. et al. TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca2+ current and Ca2+ transients. FEBS Lett 1995; 376 (1–2): 24–30.
- Sanders, DB, Larson DF Jablonowski C Olsen L. Differential expression of inducible nitric oxide synthase in septic shock. J Extracorporeal Tech 1999; 31: 118–24.
- Lowenstein CJ Alley EW Raval P et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 1993; 90 (20): 9730–4.
- Xie QW Kashiwabara Y Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide syn-thase. J Biol Chem 1994; 269 (7): 4705–8.
- Drexler H Kastner S Strobel A Studer R Brodde OE Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human Heart. J Am Coll Cardiol 1998; 32 (4): 955–63.
- Paulus WJ Bronzwaer J.G. Myocardial contractile effects of nitric oxide. Heart Fail Rev 2002; 7 (4): 371–83.
- Drexler H. Nitric oxide synthases in the failing human Heart: a doubled-edged sword. Circulation 1999; 99 (23): 2972–5.
- Yang B Larson DF Watson R.R. Inducible nitric oxide synthase (iNOS) and Heart failure. In: RR Watson, VR Preedy, eds. Nutrition and Heart disease. CRC Press, New York, 2004: 333–50.
- Sliwa, K, Woodiwiss A Kone V. et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pen-toxifylline: results of a randomized study. Circulation 2004; 109 (6): 750–5.
- 52 Sliwa, K, Woodiwiss, A, Candy, G et al. Effects of pentox-ifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive Heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 90 (10): 1118–22.
- Sliwa K Skudicky D Candy G Bergemann A Hopley M Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002; 4 (3): 305–9.
- Deswal A Bozkurt B Seta Y et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced Heart failure. Circulation 1999; 99 (25): 3224–6.
- Mann DL McMurray JJ Packer M et al. Targeted anti-cytokine therapy in patients with chronic Heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109 (13): 1594–602.
- Siwik DA Chang DL Colucci W.S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86 (12): 1259–65.
- Ohtsuka T Hamada M Saeki H et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopa-thy and effect of carvedilol on these levels. Am J Cardiol 2003; 91 (8): 1024–7, A8.
-
Dixon WG
Watson K
Lunt M
Hyrich KL
Silman AJ
Symmons D.P.
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatol-ogy Biologics Register.
Arthritis Rheum
2006;
54
(8):
2368–76.
10.1002/art.21978 Google Scholar
- Marzo-Ortega H McGonagle D Haugeberg G Green MJ Stewart SP Emery P. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003; 62 (10): 1020–1.
